Indeed, treatment with an anti-VISTA antibody significantly reduced LUSC tumor growth in WT, but not mLST8 KO cells, indicating that both the mTORC2-dependent effects, including those that drive glycolysis and PSGL-1 expression have dramatic impacts on LUSC, at least in part, through modulating anti-tumor immune response. This evidence concerns the gene VSIR and neoplasm.